Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PZZ
|
|||
| Former ID |
DIB006209
|
|||
| Drug Name |
Lypressin
|
|||
| Synonyms |
Lysine-vasopressin; Lysine-8-vasopressin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Amnesia [ICD-11: MB21.1; ICD-10: R41, R41.3] | Approved | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C46H65N13O12S2
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCCN)C(=O)NCC(=O)N
|
|||
| InChI |
1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
|
|||
| InChIKey |
BJFIDCADFRDPIO-DZCXQCEKSA-N
|
|||
| CAS Number |
CAS 50-57-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:94802
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1 receptor (V1R) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2172). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.